Haiying Zhan, MD, PhD
Assistant Professor of PathologyCards
About
Research
Publications
2025
Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers
Foldi J, Xiong K, Liu M, Robbins C, Chen F, Zhan H, Burela S, Dai J, Karn P, Dugo M, Bianchini G, Lee A, Oesterreich S, Rimm D, Pusztai L. Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers. JCO Precision Oncology 2025, 9: e2500529. PMID: 41237360, DOI: 10.1200/po-25-00529.Peer-Reviewed Original ResearchConceptsPrimary breast cancerBreast cancerMolecular subtypesClinical outcomesEstrogen receptor (ER)-negativeClinical outcomes of patientsHigh recurrence scoreOutcomes of patientsTumor cell populationDigital spatial profilingMolecular featuresER-highER-lowPreoperative chemotherapyER-negativeER-positiveRecurrence scoreER expressionEndocrine-resistantEndocrine resistanceChemotherapy strategiesChemotherapy sensitivityIntratumoral heterogeneityPositive cellsER heterogeneityInvasive breast carcinoma in a patient with PHTS: a case report
Zhan H, Fischbach N, Lynch M, Liang Y, Krishnamurti U, Cohen P. Invasive breast carcinoma in a patient with PHTS: a case report. Diagnostic Pathology 2025, 20: 120. PMID: 41107919, PMCID: PMC12532417, DOI: 10.1186/s13000-025-01715-1.Peer-Reviewed Original ResearchConceptsPTEN hamartoma tumor syndromeAtypical ductal hyperplasiaHamartoma tumor syndromeTumor syndromeFamily historyBilateral palpable breast massesFocal atypical ductal hyperplasiaFamily history of cancerInvasive breast carcinomaPalpable breast massesEctopic breast tissueBloody nipple dischargeAxillary lymph nodesGermline pathogenic variantsHistory of cancerCase presentationWeInvasive carcinomaBreast carcinomaDuctal hyperplasiaMastectomy specimensNipple dischargeRight breastBenign papillomasMultiple biopsiesPapillary proliferationInterobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study
Korie U, Ai D, Podany P, Zhang H, Zhan H, Kahila M, Colon-Cartagena L, Wei S, Sun H, Du J, Krishnamurti U, Liang Y. Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study. American Journal Of Clinical Pathology 2025, 164: 704-711. PMID: 40994034, DOI: 10.1093/ajcp/aqaf088.Peer-Reviewed Original ResearchConceptsDuctal carcinoma in situAtypical ductal hyperplasiaCarcinoma in situSpindle-shaped nucleiAssociated with carcinomaIndividual histologic featuresHistological featuresInterobserver agreementDuctal hyperplasiaBreast pathologistsBiopsy casesCases of atypical ductal hyperplasiaLow-grade ductal carcinoma in situEpithelial cellsClinical follow-up dataLesion extentHistological analysisDiagnostic gray zoneMulti-institutional studyVariable interobserver agreementFollow-up dataModerate to substantial agreementDuct involvementHistologic reviewRadiological findingsEstrogen receptor conversion in bone, liver and lung metastases from breast cancer
Podany P, Zhan H, Ai D, Krishnamurti U, Liang Y. Estrogen receptor conversion in bone, liver and lung metastases from breast cancer. Pathology - Research And Practice 2025, 275: 156222. PMID: 40967162, DOI: 10.1016/j.prp.2025.156222.Peer-Reviewed Original ResearchER conversionPrimary tumorTumor gradeGrade of primary tumorAssociated with worse prognosisMetastasis to boneBreast cancer treatmentMetastatic sitesER-positiveMedian survivalTP53 mutationsLiver metastasesPR positivityPIK3CA mutationsReceptor conversionClinicopathological factorsLung metastasesWorse prognosisNo significant differenceTumor typesBreast cancerGenetic alterationsMetastasisPatient managementTumorQuantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS
Zhan H, Chan N, Khaimova R, Aung T, Gaule P, Robbins C, Rimm D. Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS. Breast Cancer Research And Treatment 2025, 213: 273-279. PMID: 40679712, DOI: 10.1007/s10549-025-07781-9.Peer-Reviewed Original ResearchConceptsDuctal carcinoma in situIntermediate-grade ductal carcinoma in situHigh-grade ductal carcinoma in situInvasive carcinomaHER2 expressionHER2 levelsBloom Richardson histological grading systemDuctal carcinoma in situ casesGrading systemFFPE tumor specimensAssessment of HER2 expressionCarcinoma in situHER2 protein expressionInvasive ductal carcinomaNuclear grading systemHER2 expression levelsHistological grading systemNo significant statistical differenceHER2 immunohistochemical scoresHER2 biologyExpression levelsDuctal carcinomaNuclear gradeTumor specimensHistopathological gradeScreening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer
Huang S, Westvold S, Soulos P, Fan J, Winer E, Zhan H, Lustberg M, Lewin J, Robinson T, Dinan M. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Network Open 2025, 8: e255322. PMID: 40232715, PMCID: PMC12000969, DOI: 10.1001/jamanetworkopen.2025.5322.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityBreast cancer mortalityBreast cancer diagnosisCancer-specific mortalityCancer mortalityCancer diagnosisScreening mammographyHazard of breast cancer-specific deathFee-for-service Medicare Parts AAssociated with reduced breast cancer mortalityLower breast cancer mortalityHazard of breast cancer-specific mortalityBreast cancerImprove breast cancer outcomesScreen-detected breast cancerCohort studyBreast cancer-specific deathStudy of older womenBreast cancer outcomesFee-for-serviceDetection of breast cancerMedicare Part ALater-stage diseaseCox proportional hazards modelsAssociated with early stagesPTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence
Zhan H, Antony V, Tang H, Theriot J, Liang Y, Hui P, Krishnamurti U, DiGiovanna M. PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence. Breast Cancer Research And Treatment 2025, 211: 441-447. PMID: 40063317, DOI: 10.1007/s10549-025-07660-3.Peer-Reviewed Original ResearchConceptsPten inactivating mutationsBreast cancerER+/HER2- tumorsRecurrent tumorsER+/HER2- breast cancer patientsInactivating mutationsAssociated with worse clinical outcomesTreatment historyER+/HER2- breast cancerTriple negative phenotypeBreast cancer recurrenceBreast cancer patientsHormone receptor lossResultsThe average timeHR+ tumorsDistant recurrenceHR statusER expressionRecurrent diseaseTumor histologyTumor recurrenceHER2 expressionHormone independencePatient ageClinicopathological characteristics116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast Cancer
Babb P, Theriot J, Liang Y, Cartagena L, Buza N, Krishnamurti U, Zhan H. 116 Pathological and Molecular Characterization of Estrogen Receptor-Positive/HER2-Negative de novo Metastatic Breast Cancer. Laboratory Investigation 2025, 105: 102340. DOI: 10.1016/j.labinv.2024.102340.Peer-Reviewed Original Research270 Pathological Response to Herceptin-containing Neoadjuvant Therapy in HER2 IHC2+/ISH+ and IHC3+ Early-Stage Breast Cancers
Zhan H, Chan N, Rimm D. 270 Pathological Response to Herceptin-containing Neoadjuvant Therapy in HER2 IHC2+/ISH+ and IHC3+ Early-Stage Breast Cancers. Laboratory Investigation 2025, 105: 102494. DOI: 10.1016/j.labinv.2024.102494.Peer-Reviewed Original Research214 Histologic Analysis and Clinical Correlation of Atypical Apocrine Lesions
Podany P, Zhan H, Cartagena L, Krishnamurti U, Liang Y. 214 Histologic Analysis and Clinical Correlation of Atypical Apocrine Lesions. Laboratory Investigation 2025, 105: 102438. DOI: 10.1016/j.labinv.2024.102438.Peer-Reviewed Original Research